Up-to-date treatment and management of myositis

Nicolò Pipitone, Carlo Salvarani

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE OF REVIEW: Myositis, or idiopathic inflammatory myopathy, is an overarching concept that includes dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome. Glucocorticoids are still considered the mainstay of treatment of myositis but some patients require add-on immunosuppressive therapy because of insufficient response to glucocorticoids, relapses when glucocorticoids are tapered, or because they incur glucocorticoid-related side effects.

RECENT FINDINGS: The goal of this article was to review (PubMed search from January 2019 through June 2020) the efficacy and safety of standard and novel agents used in adult dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome.

SUMMARY: Established therapies beyond glucocorticoids continue to have a major role in managing patients with myositis. In addition, novel agents are being tried for refractory manifestations of myositis.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume32
Issue number6
DOIs
Publication statusPublished - Nov 2020

Fingerprint Dive into the research topics of 'Up-to-date treatment and management of myositis'. Together they form a unique fingerprint.

Cite this